Citable filing context
ABBV's research view summarizes recent SEC filing context, starting with debt_offering from Aug 18, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 18, 2026 | debt_offering | AbbVie completed a $10 billion senior notes offering to fund its acquisition of Apogee Therapeutics, Inc. |
| Aug 5, 2026 | debt_offering | AbbVie issued $9.93 billion in senior notes to fund the acquisition of Apogee Therapeutics, Inc. |
| Jul 31, 2026 | earnings | AbbVie reported second-quarter 2026 net revenues of $16.99 billion and announced a definitive agreement to acquire Apogee Therapeutics. |
| Jul 31, 2026 | Guidance: adjusted_diluted_eps | 13.87 to 14.07 |
| Jul 6, 2026 | Guidance: adjusted_diluted_eps | 3.57 to 3.61 |
| Jul 6, 2026 | Guidance: adjusted_diluted_eps | 13.91 to 14.11 |
| Aug 3, 2026 | mda_quarterly | AbbVie reported strong financial performance for the first half of 2026, with worldwide net revenues of $32.0 billion, an 11% increase on a reported basis. Growth was primarily driven by the immunology portfolio, specifically Skyrizi and Rinvoq, which saw revenue increases of 27% and 24%, respectively. Conversely, Humira revenues declined 37% due to biosimilar competition. Neuroscience remains a key growth pillar, with Vraylar, Ubrelvy, and Qulipta showing double-digit revenue gains. The company maintains a robust pipeline with approximately 90 programs, including 60 in mid-to-late-stage development. Strategic capital allocation remains focused on R&D and business development, highlighted by a definitive agreement to acquire Apogee Therapeutics for $10.9 billion, expected to close in the third quarter of 2026. To support this, AbbVie secured a $10.0 billion term loan facility. Operational risks include ongoing litigation, such as the Allergan breast implant product liability cases, for which a resolution was reached in June 2026. Additionally, the company faces regulatory pressure from the Inflation Reduction Act, with Botox selected for Medicare price negotiations beginning in 2028. AbbVie’s liquidity remains strong, supported by $6.6 billion in cash and equivalents and investment-grade credit ratings. |
| May 8, 2026 | mda_quarterly | AbbVie executed significant share repurchases during the first quarter of 2026, acquiring a total of 4,623,720 shares. The bulk of this activity occurred in March, with 4,621,835 shares purchased at an average price of $230.40, largely under a publicly announced program. Minor repurchases also took place in January (976 shares at $222.49) and February (909 shares at $223.56), with some shares allocated to the employee stock purchase plan. Following these transactions, approximately $1.83 billion remained authorized for future share repurchases. For the quarter ended March 31, 2026, no directors or officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements. The filing further details the company's employee equity compensation framework, including Performance-Vested Restricted Stock Units, Performance Share Awards, and Non-Qualified Stock Options, outlining their vesting conditions, forfeiture clauses, and tax withholding mechanisms, which are integral to AbbVie's long-term incentive structure. |
Source: SEC EDGAR filing text and events; period Aug 18, 2026; filed Aug 18, 2026.
ABBV company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.